PCN37 PRELIMINARY COST-CONSEQUENCE ANALYSIS OF EPIRUBICIN/CISPLATIN/5FU (ECF) COMPARED TO EPIRUBICIN/CISPLATIN/CAPECITABINE (ECX) IN PATIENTS WITH ADVANCED OESOPHAGOGASTRIC CANCER
Abstract
Authors
AM Horgan J Knox G Liu PA Bradbury C Sahi NB Leighl